Siemens Healthineers stock hits 52-week low on sales slowdown

Siemens Healthineers stock plunges to 52-week low amid healthcare policy shifts

Siemens Healthineers has seen its stock price tumble to a new 52-week low, closing at €35.66 by the end of last week. The medical technology firm, known for its advanced imaging and diagnostic equipment, now faces growing concerns over slowing sales and policy shifts in healthcare funding.

Analysts have cut expectations, forecasting just 3% organic sales growth and a 16% drop in profits for the second quarter of 2026. The company's shares have lost nearly 20% of their value since the start of the year. Deutsche Bank recently downgraded its rating to 'Hold', adding to investor unease. Meanwhile, Barclays and RBC have kept their price targets steady at €55.00, suggesting some confidence in a potential rebound.

A political push from North Rhine-Westphalia could soon require patients to see a GP before visiting specialists. If rolled out nationwide from 2028, this change may reduce specialist appointments, directly affecting demand for Siemens Healthineers' high-end equipment. Hospitals and clinics, already cautious about spending, might delay upgrades to imaging and diagnostic tools.

Further pressure comes from ongoing debates over statutory health insurance funding. A possible spending freeze could tighten budgets, making large investments in medical technology even less likely. The broader healthcare sector, including Siemens AG's parent company, has also felt the strain, with shares down around 5.3% since January. The combination of weaker financial forecasts, policy changes, and tighter healthcare budgets has weighed heavily on Siemens Healthineers' stock. With specialist referrals potentially declining and hospitals cutting costs, the company's core market faces long-term challenges. Investors will now watch closely for signs of stabilisation in sales and policy developments.